University of Adelaide reproductive experts have developed the world’s
first screening test which can predict a woman’s risk of developing one
or more of the four common pregnancy complications. Researchers
have developed algorithms (or calculations) that combine subtle
variations in DNA sequences in genes involved in placental development
with clinical, socioeconomic, lifestyle and family history data that can
predict a woman’s risk of having a pregnancy complication.
Professor Claire Roberts
says this new screening test can be used in early pregnancy and will
allow clinicians to initiate treatments for women at risk earlier,
helping to reduce the severity of, or prevent, the complications.
“On
average, 25% of first pregnancies in Australia are affected by one of
the four major complications: preeclampsia, preterm birth, intrauterine
growth restriction and gestational diabetes,” Professor Roberts says.
“The
health issues for babies whose mothers experience pregnancy
complications range from childhood obesity, mild learning and
behavioural problems to severe disabilities such as cerebral palsy,
intellectual handicap and blindness or even death. The women and babies
affected by these complications are also at higher risk for developing
adult onset diseases, including cardiovascular disease and type 2
diabetes.
“The screening test identifies a woman’s risk for
pregnancy complications and what those complications may be, which
allows for earlier intervention and treatment. For example, if it is
identified in early pregnancy that a woman is at risk of developing
preeclampsia, low dose aspirin before 16 weeks’ gestation could delay
the onset of the condition or prevent it completely,” she says.
Professor Roberts says early trials of the screening test have been highly successful.
“The
algorithms have been developed in over 3,200 pregnant women in Adelaide
and Auckland (New Zealand) and successfully identify each woman’s risk
of developing one of the four major pregnancy complications,” Professor
Roberts says.
“The next step is to test women right across
Australia and commercialise the algorithms so that they can be offered
to pregnant women by clinicians from all over the world,” she says.
The
University’s commercialisation company, Adelaide Research &
Innovation (ARI), is supporting the commercial development of the
technology. For more information, visit www.adelaideresearch.com.au.